XML 21 R2.htm IDEA: XBRL DOCUMENT v3.20.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 13,644 $ 10,575
Restricted cash 270 269
Marketable securities 125,681 152,714
Interest and other receivables 802 1,168
Prepaid and other current assets 1,211 1,332
Total current assets 141,608 166,058
Noncurrent marketable securities 19,651 18,582
Property and equipment, net 408 59
Operating leases, right-of-use assets 2,497  
Deposits and other assets 1,353 585
Total assets 165,517 185,284
Current liabilities:    
Accounts payable 1,181 982
Accrued compensation and benefits 4,830 2,642
Amount due to Janssen Biotech, Inc. 14,269 2,610
Operating lease liabilities 354  
Accrued liabilities 7,528 1,317
Total current liabilities 28,162 7,551
Noncurrent operating lease liabilities 2,200  
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and 2018
Common stock, $0.001 par value; 450,000,000 shares authorized; 199,814,581 and 186,392,682 shares issued and outstanding at December 31, 2019 and 2018, respectively 200 186
Additional paid-in capital 1,214,835 1,189,194
Accumulated deficit (1,080,012) (1,011,464)
Accumulated other comprehensive gain (loss) 132 (183)
Total stockholders' equity 135,155 177,733
Total liabilities and stockholders' equity $ 165,517 $ 185,284